Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16651202 | 0.92 | RORC (1.00) | RORC | |
| SCHEMBL16662025 | 0.91 | RORC (0.88) | RORC | |
| SCHEMBL19052192 | 0.91 | RORC (1.00) | RORC | |
| SCHEMBL16651844 | 0.90 | RORC (1.00) | RORC | |
| SCHEMBL16656111 | 0.88 | RORC (1.00) | RORC | |
| SCHEMBL19064770 | 0.88 | RORC (1.00) | RORC | |
| SCHEMBL16651944 | 0.88 | RORC (0.82) | RORC | |
| SCHEMBL15647119 | 0.87 | RORC (1.00) | RORC | |
| SCHEMBL16473450 | 0.86 | RORC (1.00) | RORC | |
| SCHEMBL16459708 | 0.84 | RORC (0.85) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057422-B1 | QUINOLINYL MODULATORS OF ROR(GAMMA)T | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-15 | — | — | EP | disclosed |
| EP-3057422-B1 | QUINOLINYL MODULATORS OF ROR(GAMMA)T | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-15 | — | — | EP | disclosed |
| US-10201546-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-12 | — | — | US | disclosed |
| US-20170182056-A1 | QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-29 | — | — | US | disclosed |
| US-20170182056-A1 | QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-29 | — | — | US | disclosed |
| US-9624225-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-18 | — | — | US | disclosed |
| US-9624225-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-18 | — | — | US | disclosed |
| EP-3057422-A1 | QUINOLINYL MODULATORS OF ROR(GAMMA)T | Janssen Pharmaceutica NV (BE) | 2016-08-24 | — | — | EP | disclosed |
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | JOHNSON & JOHNSON (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2015057626-A1 | QUINOLINYL MODULATORS OF RORyT | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | JOHNSON & JOHNSON (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | RORC 1/4885 |
| US-10201546-B2 | Quinolinyl modulators of RORγt | RORC, RORB, RORA | RORC 1/4885 |
| US-20170182056-A1 | QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | RORC 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.